wp-cerber
domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init
action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/htdocs/w00e14a1/CPC-NEU2021/wp-includes/functions.php on line 6114[et_pb_section fb_built=»1″ admin_label=»Header» _builder_version=»4.16″ _module_preset=»default» background_color=»RGBA(255,255,255,0)» background_image=»https:\/\/www.chameleon-pharma.com\/wp-content\/uploads\/bady-abbas-c4XoMGxfsVU-unsplash-scaled.jpg» background_blend=»color» height=»200px» max_height=»200px» custom_margin=»-15px||||false|false» custom_padding=»||||false|false» locked=»off» global_colors_info=»{}»][et_pb_row make_equal=»on» custom_padding_last_edited=»on|tablet» _builder_version=»4.16″ _module_preset=»default» custom_margin=»0px||||false|false» custom_padding=»||||false|false» custom_padding_tablet=»0px||0px||true|false» custom_padding_phone=»0px||0px||true|false» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» custom_css_main_element=»margin: auto;» global_colors_info=»{}»][et_pb_text _builder_version=»4.16″ _module_preset=»default» header_font=»|700|||||||» header_text_color=»#FFFFFF» header_font_size=»45px» header_font_size_tablet=»45px» header_font_size_phone=»35px» header_font_size_last_edited=»on|phone» global_colors_info=»{}»]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»Image left, text right» _builder_version=»4.16″ custom_padding=»0|0px|0px|0px|false|false» locked=»off» global_colors_info=»{}»][et_pb_row column_structure=»1_2,1_2″ use_custom_gutter=»on» custom_padding_last_edited=»on|tablet» padding_top_bottom_link_2=»true» padding_left_right_link_2=»false» _builder_version=»4.16″ width=»100%» width_tablet=»80%» width_phone=»80%» width_last_edited=»on|tablet» max_width=»100%» max_width_tablet=»80%» max_width_phone=»80%» max_width_last_edited=»on|tablet» module_alignment=»left» custom_margin=»||40px||false» custom_padding=»0|12%|0|0px|false|false» custom_padding_tablet=»|0%||» custom_padding_phone=»» module_alignment_tablet=»center» module_alignment_phone=»center» module_alignment_last_edited=»on|tablet» use_custom_width=»on» width_unit=»off» custom_width_percent=»100%» locked=»off» global_colors_info=»{}»][et_pb_column type=»1_2″ _builder_version=»4.16″ custom_padding=»|||» global_colors_info=»{}» custom_padding__hover=»|||»][et_pb_image src=»https:\/\/www.chameleon-pharma.com\/wp-content\/uploads\/maheshkumar-painam-HF-lFqdOMF8-unsplash-scaled.jpg» alt=»Parliament in Berlin, Germany, with the German flag in the wind» title_text=»Berlin Parliament» show_bottom_space=»off» force_fullwidth=»on» align_tablet=»center» align_phone=»center» align_last_edited=»on|desktop» _builder_version=»4.16″ background_color_gradient_direction=»90deg» background_color_gradient_start=»#404451″ background_color_gradient_end=»rgba(240,242,246,0)» custom_padding=»||||false|false» custom_padding_tablet=»||60px|» custom_padding_phone=»||10px||false|false» custom_padding_last_edited=»on|phone» animation_style=»slide» animation_direction=»left» animation_intensity_slide=»1%» global_colors_info=»{}»][\/et_pb_image][et_pb_text _builder_version=»4.16″ _module_preset=»default» text_font_size=»13px» custom_padding=»|||60px||» global_colors_info=»{}»]<\/p>\n
Featured image: Photo by Maheshkumar Painam<\/a> on Unsplash<\/a><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=»1_2″ _builder_version=»4.16″ custom_padding=»6vw||6vw|» custom_padding_tablet=»0px|0px|0px|0px|false|true» custom_padding_phone=»||||false|false» custom_padding_last_edited=»on|tablet» global_colors_info=»{}» padding_phone=»||||false|false» padding_tablet=»|10%||10%|false|true» padding_last_edited=»on|tablet» custom_padding__hover=»|||»][et_pb_text _builder_version=»4.17.4″ text_font=»||||||||» header_font=»||||||||» header_3_text_color=»#3550a0″ header_6_font=»||||||||» max_width=»853px» custom_margin=»-78px|1px||||» custom_padding=»|0px||||» hover_enabled=»0″ header_3_font_size_tablet=»» header_3_font_size_phone=»20px» header_3_font_size_last_edited=»on|desktop» locked=»off» global_colors_info=»{}» sticky_enabled=»0″]<\/p>\n Germany is the strongest OTC and Rx market in Europe and the evolution of its demographics is a source of opportunities if you are looking to expand your business to the European region.\u00a0<\/span><\/i><\/p>\n A strong coun\u00adtry in West\u00adern Europe with a rich his\u00adtory, Ger\u00admany is home to the old\u00adest uni\u00adver\u00adsal health\u00adcare sys\u00adtem, dat\u00ading back to social legislation from the Bis\u00admarck Repub\u00adlic. In the last 20 years, life expectancy has increased by four years for women and five years for men, reach\u00ading an aver\u00adage of 80.<\/span><\/p>\n Since reunification in 1990, Ger\u00admany has expended con\u00adsid\u00ader\u00adable funds to harmonize pro\u00adduc\u00adtiv\u00adity and wages across the coun\u00adtry, and pros\u00adper\u00adity has increased on the basis of Ger\u00adman exports, par\u00adtic\u00adu\u00adlarly machin\u00adery, vehi\u00adcles, met\u00adals, chem\u00adi\u00adcals and other goods nec\u00ades\u00adsary in Emerg\u00ading Mar\u00adkets.<\/span><\/p>\n Accord\u00ading to the World Health Organ\u00adi\u00adza\u00adtion (WHO), <\/span>Germany\u2019s dis\u00adease profile reflects its high-income sta\u00adtus<\/b>: heart dis\u00adease and stroke are the most com\u00admon causes of death, fol\u00adlowed by can\u00adcer, par\u00adtic\u00adu\u00adlarly of the lung and colon. The gen\u00aderal can\u00adcer mor\u00adtal\u00adity rate is lower than the EU aver\u00adage, but it is slightly higher for breast can\u00adcer. Around 28% of the population smokes (Macrotrend.net and Gbe-bud), a relatively high rate. Just under one in four adults in Germany are obese. As a result, Germans live on average 2.6 years less due to being overweight. Being overweight accounts for 10.7% of health expenditure. At a rate of 15,3%, the rate of diabetes in the country places Germany first in Europe.\u00a0<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=»4.17.4″ _module_preset=»default» min_height=»330.4px» custom_margin=»-28px|auto||auto||» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n Nevertheless, <\/span>Germany places a lot of emphasis on health<\/b>, which is evident in the OTC market: The<\/span> revenue of OTC grew by 3,7% in 2019<\/b>, reaching a worth of USD 11,4 billion. The German OTC and pharma market in 2019 amounted to USD 49 billion, at ex-factory price, experiencing a growth of 5,1% between 2014 and 2019. According to our forecast, it should be <\/span>worth USD 82 Billion by <\/b>2035<\/b>.<\/b><\/p>\n Compared to Europe, the German market is the biggest pharmaceutical market.\u00a0<\/b><\/p>\n Despite tough pric\u00ading and reim\u00adburse\u00adment con\u00addi\u00adtions, as well as the challenging effects of patent expi\u00adra\u00adtions, Ger\u00admany remains one of the largest global phar\u00adma\u00adceu\u00adti\u00adcal mar\u00adkets, and that status will con\u00adtinue to increase its rewards. Investors still see Ger\u00admany as a solid propo\u00adsi\u00adtion.<\/span><\/p>\n \n If you are planning on entering Germany, our expertise and long standing network can support you. The Chameleon Pharma Consulting Group has extensive OTC and pharma expertise in European markets, and we would be thrilled to support you to take advantage of the opportunities Germany has to offer!<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»Expert Knowledge» _builder_version=»4.16″ _module_preset=»default» min_height=»609.2px» custom_margin=»-67px||-121px|||» custom_padding=»36px|||||» locked=»off» global_colors_info=»{}»][et_pb_row admin_label=»Row» _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.16″ _module_preset=»default» min_height=»45px» custom_margin=»30px|||||» custom_padding=»||0px|||» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_2,1_2″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_2″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_icon font_icon=»||divi||400″ icon_color=»#001389″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_icon][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n OTC and pharma market size, ex-factory<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=»1_2″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_icon font_icon=»||divi||400″ icon_color=»#001389″ _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»][\/et_pb_icon][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»]<\/p>\n OTC and pharma market growth<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»Number Counter» _builder_version=»4.16″ _module_preset=»default» background_color=»#EEEEEE» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Total population» number=»79 903 481 » percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Male\/Female » number=»0.96″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Population growth» number=»-0.21%» percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Birth rate» number=»8.6\/1000″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Mortality rate » number=»13.2\/1000″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Life expectancy» number=»81 years» percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_cta title=»Interested in this market?» button_url=»https:\/\/www.chameleon-pharma.com\/contacts\/» button_text=»Click Here» _builder_version=»4.16″ _module_preset=»default» background_color=»#0B0B7A» global_colors_info=»{}»]<\/p>\n <\/span><\/p>\n We are ready to support you in\u00a0<\/span>Strategy, Marketing, Systematic International Company Partner Identification, Commercial Due Diligence, Business Development, Acquisition Search, Regulatory\u00a0projects,<\/span>\u00a0and more in order to ensure your growth.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n [\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" GermanyFeatured image: Photo by Maheshkumar Painam on UnsplashGermany: The biggest European OTC and Rx market\u00a0 Germany is the strongest OTC and Rx market in Europe and the evolution of its demographics is a source of opportunities if you are looking to expand your business to the European region.\u00a0 A strong coun\u00adtry in West\u00adern Europe with […]<\/p>\n","protected":false},"author":7,"featured_media":0,"parent":8782,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[caption id=\"attachment_928\" align=\"alignleft\" width=\"300\"] Brandenburger Tor, Berlin, Germany<\/a> by Luke Ma<\/a> with CC<\/a>[\/caption]\r\n\r\nA strong coun\u00adtry in West\u00adern Europe with a rich his\u00adtory, Ger\u00admany is home to the old\u00adest uni\u00adver\u00adsal health\u00adcare sys\u00adtem<\/strong>, dat\u00ading back to social legislation from the Bis\u00admarck Repub\u00adlic. In the last 20 years, life expectancy<\/strong> has increased by four years for women and five years for men, reach\u00ading an aver\u00adage of 80.<\/strong>\r\n\r\nSince reunification in 1990, Ger\u00admany has expended con\u00adsid\u00ader\u00adable funds to har\u00admonise pro\u00adduc\u00adtiv\u00adity and wages across the coun\u00adtry, and pros\u00adper\u00adity has increased on the basis of Ger\u00adman exports, par\u00adtic\u00adu\u00adlarly machin\u00adery, vehi\u00adcles, met\u00adals, chem\u00adi\u00adcals and other goods nec\u00ades\u00adsary in Emerg\u00ading Mar\u00adkets.\r\n\r\nAccord\u00ading to the World Health Organ\u00adi\u00adza\u00adtion (WHO), Germany\u2019s dis\u00adease profile reflects its high-income sta\u00adtus: heart dis\u00adease and stroke are the most com\u00admon causes of death, fol\u00adlowed by can\u00adcer, par\u00adtic\u00adu\u00adlarly of the lung and colon. The gen\u00aderal can\u00adcer mor\u00adtal\u00adity rate is lower than the EU aver\u00adage, but it is slightly higher for breast can\u00adcer. Com\u00admu\u00adni\u00adca\u00adble dis\u00adeases account for just 5% of life years lost. Around 24% of the pop\u00adu\u00adla\u00adtion smokes, a rel\u00ada\u00adtively high rate, and the obe\u00adsity rate at 14.7% (found using self-reported weight and height data) is also cause for con\u00adcern. At almost 9%, the rate of dia\u00adbetes in the 20+ age group places Ger\u00admany fourth in the world after the US, Canada and Mex\u00adico.\r\n\r\nNev\u00ader\u00adthe\u00adless, Ger\u00admans place a lot of empha\u00adsis on health, which is evi\u00addent in the OTC mar\u00adket, grow\u00ading at a rate of 2.4%. The OTC mar\u00adket in Ger\u00admany is worth US $5.39 bil\u00adlion\u2014high com\u00adpared to markets in other West\u00adern Euro\u00adpean coun\u00adtries.\r\n\r\nThe Ger\u00adman pop\u00adu\u00adla\u00adtion (approx\u00adi\u00admately 80 mil\u00adlion people) pay an aver\u00adage of US $110 per year for OTC prod\u00aducts, which make up 11% of the total health\u00adcare mar\u00adket, in phar\u00adma\u00adcies. Sixty-two per\u00adcent of phar\u00adma\u00adceu\u00adti\u00adcals pro\u00adduced in Ger\u00admany are exported, mak\u00ading exports a cru\u00adcial area for the indus\u00adtry and vul\u00adner\u00ada\u00adble to the fate of Euro\u00adpean cur\u00adren\u00adcies. The phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry is just as strong as the country\u2019s econ\u00adomy as a whole.\r\n\r\nThe German phar\u00adma\u00adceu\u00adti\u00adcal mar\u00adket size in 2012 amounted to US $49 bil\u00adlion; this, in com\u00adpar\u00adi\u00adson to East\u00adern Europe, is a rel\u00ada\u00adtively gigan\u00adtic mar\u00adket. With a pro\u00adjected annual mar\u00adket growth of 2.1% per year until 2018, the phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry is expected to grow to US $55.51 bil\u00adlion. Fur\u00adther remark\u00adable is the low share of inter\u00adna\u00adtional prod\u00aducts in Ger\u00admany: 50%.\r\n\r\nThe German phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry employs 105,000 peo\u00adple. In 2012 more than 903 phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpa\u00adnies were reg\u00adis\u00adtered in Ger\u00admany. (This exclud\u00ades OTC com\u00adpa\u00adnies.) Nev\u00ader\u00adthe\u00adless, there is a need for inno\u00adv\u00ada\u00adtive and niche prod\u00aducts in this coun\u00adtry.\r\n\r\nInno\u00adva\u00adtion is a dri\u00adving force for the suc\u00adcess\u00adful devel\u00adop\u00adment of phar\u00adma\u00adceu\u00adti\u00adcal com\u00adpa\u00adnies. Research and devel\u00adop\u00adment in the phar\u00adma\u00adceu\u00adti\u00adcal indus\u00adtry aim to expand the pos\u00adsi\u00adbil\u00adi\u00adties for diag\u00adno\u00adsis and causal and symp\u00adto\u00admatic ther\u00adapy, as well as develop dis\u00adease pre\u00adven\u00adtion mea\u00adsures and fill gaps. Drugstores have a big influence in Germany; the chains dm and Ross\u00adman offer many OTC prod\u00aducts. Since 1999 OTC prod\u00aducts have been permitted to be sold in drug\u00adstores, but phar\u00admacy chains are still sub\u00adject to restric\u00adtions.\r\n\r\nGer\u00admany has 21,000 phar\u00adma\u00adcies, with a citizen-to-pharmacy ratio of 3,900 peo\u00adple per phar\u00admacy. The mail-order and Inter\u00adnet phar\u00admacy mar\u00adkets are also grow\u00ading dra\u00admat\u00adi\u00adcally: these sec\u00adtors have increased more than 30% in the last three years. The aver\u00adage growth of mail-order phar\u00adma\u00adcies is esti\u00admated at 7% per year, with a mar\u00adket worth around US $1.9 bil\u00adlion in 2012. What\u2019s more, the country\u2019s ageing pop\u00adu\u00adla\u00adtion will need new and more effective ther\u00ada\u00adpies in the com\u00ading years, par\u00adtic\u00adu\u00adlarly in treat\u00adments for can\u00adcer, heart dis\u00adease, Alzheimer\u2019s and osteo\u00adporo\u00adsis.\r\n\r\nDespite tough pric\u00ading and reim\u00adburse\u00adment con\u00addi\u00adtions, as well as the challenging effects of patent expi\u00adra\u00adtions, Ger\u00admany remains one of the largest global phar\u00adma\u00adceu\u00adti\u00adcal mar\u00adkets, and that status will con\u00adtinue to increase its rewards. Investors still see Ger\u00admany as a solid propo\u00adsi\u00adtion, and for good rea\u00adson: unem\u00adploy\u00adment has fallen to a post-reunification low of 5.5%, and the country has a cur\u00adrent account sur\u00adplus of 5% of the GDP.\r\n\r\n","_et_gb_content_width":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-8818","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/comments?post=8818"}],"version-history":[{"count":12,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8818\/revisions"}],"predecessor-version":[{"id":17474,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8818\/revisions\/17474"}],"up":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8782"}],"wp:attachment":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/media?parent=8818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Germany: The biggest European OTC and Rx market\u00a0<\/strong><\/h2>\n
The German OTC and pharma market in 2035<\/h2>\n
USD 81,2 Billion <\/b><\/h3>\n
3-5<\/strong>%<\/strong><\/h3>\n
Germany in numbers<\/h2>\n